Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) and Leap Therapeutics (NASDAQ:LPTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.
Profitability
This table compares Actinium Pharmaceuticals and Leap Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Actinium Pharmaceuticals | N/A | -100.85% | -47.89% |
| Leap Therapeutics | N/A | -247.44% | -146.51% |
Risk and Volatility
Actinium Pharmaceuticals has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Actinium Pharmaceuticals | $90,000.00 | 443.68 | -$48.82 million | ($1.10) | -1.16 |
| Leap Therapeutics | N/A | N/A | -$67.56 million | ($1.22) | -1.68 |
Actinium Pharmaceuticals has higher revenue and earnings than Leap Therapeutics. Leap Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Leap Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Actinium Pharmaceuticals and Leap Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Actinium Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| Leap Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Actinium Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 212.50%. Given Actinium Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Actinium Pharmaceuticals is more favorable than Leap Therapeutics.
Summary
Actinium Pharmaceuticals beats Leap Therapeutics on 9 of the 12 factors compared between the two stocks.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.
About Leap Therapeutics
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
